• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Skinovation Pharm

Skinovation Pharm

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

    FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

  2. DEINOVE Enters the Cosmetic Ingredients Market with GREENTECH with the Objective of a Commercial Launch by End of 2018

    DEINOVE Enters the Cosmetic Ingredients Market with GREENTECH with the Objective of a Commercial Launch by End of 2018

  3. Global Lifestyle Drugs Market to Grow at a CAGR of 2.8% by 2017-2021, with Allergan, BMS, Eli Lilly & Pfizer Leading the Way - Research and Markets

    Global Lifestyle Drugs Market to Grow at a CAGR of 2.8% by 2017-2021, with Allergan, BMS, Eli Lilly & Pfizer Leading the Way - Research and Markets

  4. City of Hope Researchers Present New Findings at 2017 American Association for Cancer Research Annual Meeting

    City of Hope Researchers Present New Findings at 2017 American Association for Cancer Research Annual Meeting

  5. XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

    XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

  6. Press Release: FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

    Press Release: FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

  7. FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

    FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

  8. Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 4th Update

    Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 4th Update

  9. Valeant Paid CEO $62.7 Million Total -- WSJ

    Valeant Paid CEO $62.7 Million Total -- WSJ

  10. Valeant CEO Joseph Papa made $62.7 million last year

    Valeant CEO Joseph Papa made $62.7 million last year

12345

©2017 Morningstar Advisor. All right reserved.